LLY
Eli Lilly and Company
October 15, 2026 · pre-market
- Rarity
- 1.31
- Peak move
- +5.25%
- Float cap
- $1.03T
Eli Lilly and Company is a pharmaceutical company that discovers, develops, manufactures, and markets human medicines sold in roughly 90 countries. Its products span cardiometabolic health (Mounjaro, Zepbound, Jardiance, Humalog, Trulicity), oncology (Verzenio, Cyramza, Jaypirca), immunology (Taltz, Olumiant), and neuroscience (Emgality, Kisunla). Customers include wholesale distributors, hospitals, pharmacies, and government and commercial insurers.
Where do you see this going?
no votes yetVoting closed at 4:00 PM ET.
What we found
13 events · 0 from SEC or newswire · 0 timed with the moveearnings_releaseEli Lilly confirmed it will report third-quarter 2026 financial results on October 29, 2026, with a conference call at 10 a.m. Eastern time.
macro_dataUS September CPI came in above expectations, raising fears of Federal Reserve rate hikes and triggering a rotation out of AI hardware names into defensive sectors including healthcare.
analyst_ratingErste Group raised its Eli Lilly EPS estimates to $36.55 for FY2026 and $47.30 for FY2027, while BofA reiterated Buy with a $1,341 target and Morgan Stanley raised its target to $1,430 from $1,419.
- Key event
executive_remarkEli Lilly SVP Thomas Seck presented the company's next-generation obesity strategy at KIC 2026 in Seoul, citing retatrutide's up to 30.3% weight loss at 104 weeks and outlining expansion into oral drugs, amylin combinations and muscle preservation.
institutional_flowFirst Citizens Bank & Trust disclosed a 22.3% increase in its Eli Lilly holdings during the third quarter of 2026.
- Key event
macro_dataUS September CPI rose 3.7% year-over-year versus 3.6% expected, with core CPI at 2.6%, prompting traders to raise the odds of an October Fed rate hike.
peer_disclosureFrench biotech Enodia Therapeutics signed a research collaboration and license agreement with Pfizer worth potentially more than $500 million to develop Sec61 inhibitors, following Eli Lilly's expanded Sec61-targeting deal with Gate Bioscience.
product_launchEli Lilly integrated AI into its drug discovery platform, with its TuneLab unit partnering with Twist Bioscience and Ginkgo Bioworks to strengthen antibody characterization and discovery data generation.
- Key event
regulatory_approvalThe US FDA approved a new indication for Eli Lilly's pirtobrutinib for adults with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma without known 17p deletion.
regulatory_approvalThe UK MHRA authorised Eli Lilly's once-weekly Onswik (insulin efsitora alfa) for adults with type 2 diabetes, with marketing authorisation granted to Eli Lilly Nederland B.V. via the ACCESS Procedure.
analyst_ratingRBC Capital Markets said Eli Lilly is likely to raise its full-year revenue guidance by about $2 billion at Q3 results on the strength of diabetes and obesity drug sales, maintaining an Outperform rating with a $1,500 price target.
clinical_readoutPrelude Therapeutics announced a clinical trial collaboration and supply agreement with Eli Lilly under which Lilly will supply abemaciclib (Verzenio) and imlunestrant (Inluriyo) for a Phase 1 trial of Prelude's KAT6A degrader PRT13722 in HR+/HER2- breast cancer, with enrollment expected in Q4 2026.
investor_dayPrelude Therapeutics and Eli Lilly researchers presented early analyses at the ARDD conference suggesting GLP-1 drugs may slow biological aging by two to four years based on epigenetic aging clocks, though the studies have not been peer-reviewed.